Effect of lifestyle changes and atorvastatin administration on dyslipidemia in hemodialysis patients: A prospective study

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 9, 2014, Pages 443-451

  Grzegorzewska, Alicja E ^a   Niepolski, Leszek ^b   Sikora, Jan ^a   Janków, Małgorzata ^c   Jagodziński, Paweł P ^a   Sowińska, Anna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b B Braun Avitum Dialysis Center   (Poland)

^c Eurodial Dialysis Center   (Poland)

Author keywords

Atorvastatin; CD36 expression; Hemodialysis; Lifestyle changes; Salusin

Indexed keywords

ATORVASTATIN; CD36 ANTIGEN; FRUCTOSAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; MALONDIALDEHYDE OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN; SALUSIN ALPHA PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DIALYSIS MEMBRANE; DRUG DOSE INCREASE; DRUG EFFICACY; DYSLIPIDEMIA; EVENING DOSAGE; FEMALE; FOLLOW UP; FRUCTOSAMINE BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INSULIN BLOOD LEVEL; LIFESTYLE MODIFICATION; LOW FAT DIET; MALE; MIDDLE AGED; MONOCYTE; PATIENT EDUCATION; PEDOMETER; PHASE 2 CLINICAL TRIAL; PHYSICAL ACTIVITY; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THERAPY EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; BLOOD; COMPARATIVE STUDY; DYSLIPIDEMIAS; LIFESTYLE; RENAL REPLACEMENT THERAPY;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RENAL DIALYSIS;

EID: 84907681143     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2401     Document Type: Article

References (48)

1. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids. 2010; 10: 907-914.
2. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with dialysis - dependent chronic kidney disease. Am J Kidney Dis. 2003;.41: Suppl 3: S3-S91.
3. Massy ZA, Ma JZ, Louis TA, et al. Lipid-lowering therapy in patients with renal disease. Kidney Int. 1995; 48: 188-198.
4. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248.
5. Nagashima M, Watanabe T, Shiraishi Y, et al. Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis. 2010; 212: 70-77.
6. Watanabe T, Sato K, Itoh F, et al. Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease. Sensors (Basel). 2012; 12: 4974-4985.
7. Endemann G, Stanton LW, Madden KS, et al. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993; 268: 11811-11816.
8. Febbraio M, Abumrad NA, Hajjar DP, et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999; 274: 19055-19062.
9. Love-Gregory L, Sherva R, Schappe T, et al. Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile. Hum Mol Genet. 2011; 20: 193-201.
10. Brundert M, Heeren J, Merkel M, et al. Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells. J Lipid Res. 2011; 52: 745-758.
11. Feng J, Han J, Pearce SF, et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPARg. J Lipid Res. 2000; 41: 688-696.
12. Han J, Hajjar DP, Febbraio M, et al. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem. 1997; 272: 21654-21659.
13. lä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989; 84: 1086-1095.
14. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001; 108: 785-791.
15. Silverstein RL, Febbraio M. CD36 and atherosclerosis. Curr Opin Lipidol. 2000; 11: 483-491.
16. Shaw PX, Hörkkö S, Tsimikas S, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol. 2001; 21: 1333-1339.
17. Tsimikas S, Miyanohara A, Hartvigsen K, et al. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol. 2011; 58: 1715-1727.
18. Napora M, Graczykowska A, Próchniewska K, et al. Relationship between serum asymmetric dimethylarginine and left ventricular structure and function in patients with end-stage renal disease treated with hemodialysis. Pol Arch Med Wewn. 2012; 122: 226-234.
19. Opolski G, Strojek K, Kurzelewski M, et al. Cardiovascular therapy, diagnostic procedures, and control of risk factors in patients with diabetes or coronary artery disease in Poland: the Kardia-Pol registry. Pol Arch Med Wewn. 2012; 122: 413-421.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
21. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419.
22. Wanner C, Tonelli M; The Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014; 85: 1303-1309.
23. Brehm BJ, Seeley RJ, Daniels SR, et al. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab. 2003; 88: 1617-1623.
24. Jedrzejowski A, Lis D, Majcher A, et al. [Effect of lipid lowering diet on serum lipids in peritoneal dialysis patients]. Pol Merkur Lekarski. 2000; 8: 266-267. Polish.
25. Speer T, Zewinger S, Fliser D. Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transplant. 2013; 28: 2456-2463.
26. Mittman N, Desiraju B, Fazil I, et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int. 2010; 117: Suppl: S41-S45.
27. Ostrowska L, Witczak K, Adamska E. Effect of nutrition and atherogenic index on the occurrence and intensity of insulin resistance. Pol Arch Med Wewn. 2013; 123: 289-296.
28. Ravandi A, Kuksis A, Shaikh NA. Glucosylated glycerophosphoethanolamines are the major LDL glycation products and increase LDL susceptibility to oxidation: evidence of their presence in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 467-477.
29. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med. 1990; 9: 515-540.
30. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr. 1993; 57: 5Suppl:715S-724S; discussion 724S.
31. Mastalerz-Migas A, Reksa D, Pokorski M, et al. Comparison of a statin vs. hypolipemic diet on the oxidant status in hemodialyzed patients with chronic renal failure. J Physiol Pharmacol. 2007; 58: Suppl 5: 363-370.
32. Miserez AR, Rossi FA, Keller U. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects. Eur J Clin Pharmacol. 1994; 46: 107-114.
33. Sathyapalan T, Shepherd J, Coady AM, et al. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2012; 97: 3951-3955.
34. Usharani P, Mateen AA, Naidu MU, et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel group, placebo-controlled, 8-week study. Drugs R D. 2008; 9: 243-250.
35. Sozer V, Uzun H, Gelisgen R, et al. The effects of atorvastatin on oxidative stress in L-NAME-treated rats. Scand J Clin Lab Invest. 2013; 73: 591-597.
36. Elmadhun NY, Lassaletta AD, Chu LM, et al. Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome. J Thorac Cardiovasc Surg. 2012; 144: 1486-1493.
37. Fuhrman B, Koren L, Volkova N, et al. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis. 2002; 164: 179-185.
38. Masuda D, Hirano K, Oku H, et al. Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J Lipid Res. 2009; 50: 999-1011.
39. Cohen SD, Phillips TM, Khetpal P, et al. Cytokine patterns and survival in haemodialysis patients. Nephrol Dial Transplant. 2010; 25: 1239-1243.
40. Feroze U, Kalantar-Zadeh K, Sterling KA, et al. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr. 2012; 22: 317-326.
41. Yesner LM, Huh HY, Pearce SF, et al. Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler Thromb Vasc Biol. 1996; 16: 1019-1025.
42. Yuasa-Kawase M, Masuda D, Yamashita T, et al. Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases. J Atheroscler Thromb. 2012; 19: 263-275.
43. Moore KJ, Kunjathoor VV, Koehn SL, et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest. 2005; 115: 2192-201.
44. Collot-Teixeira S, Martin J, McDermott-Roe C, et al. CD36 and macrophages in atherosclerosis. Cardiovasc Res. 2007; 75: 468-477.
45. Watanabe T, Nishio K, Kanome T, et al. Impact of salusin-alpha and -beta on human macrophage foam cell formation and coronary atherosclerosis. Circulation. 2008; 117: 638-648.
46. Watanabe T, Suguro T, Sato K, et al. Serum salusin-alpha levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. Hypertens Res. 2008; 31: 463-468.
47. Watanabe T, Sato K, Itoh F, et al. The roles of salusins in atherosclerosis and related cardiovascular diseases. J Am Soc Hypertens. 2011; 5: 359-365.
48. Ti Y, Wang F, Wang ZH, et al. Associations of serum salusin-alpha levels with atherosclerosis and left ventricular diastolic dysfunction in essential hypertension. J Hum Hypertens. 2012; 26: 603-609.